Expression of cell cycle-related gene products in Langerhans cell histiocytosis

Journal of Pediatric Hematology/Oncology

Volumn 24, Issue 9, 2002, Pages 727-732

  Schouten, Bart ^a   Egeler, R Maarten ^a   Leenen, Pieter J M ^b   Taminiau, Antonie H M ^a   Van den Broek, Lambert J C M ^a   Hogendoorn, Pancras C W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Cell cycle gene products (Ki 67, TGF R, p53, MDM2, p16, Rb, p21, Bcl2); Langerhans cell histiocytosis; Proliferation

Indexed keywords

GENE PRODUCT; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P16; PROTEIN P21; PROTEIN P53; T6 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOPSY; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; DNA DAMAGE; GENE CLUSTER; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HISTIOCYTOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LANGERHANS CELL; MAJOR CLINICAL STUDY; MITOSIS INHIBITION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR GENE;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; ANTIBODIES; CELL CYCLE; GENE EXPRESSION REGULATION; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOHISTOCHEMISTRY; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RETINOBLASTOMA PROTEIN; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036901064     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200212000-00009     Document Type: Article

References (25)

1. Egeler RM, Favara BE, van Meurs M, et al. Differential in situ cytokine profiles of Langerhans-like cells and T-cells in Langerhans cell histiocytosis: Abundant expression of cytokines relevant to disease and treatment. Blood 1999;94:4195-201.
2. Willman CL, Busque L, Griffith BB, et al. Langerhans' cell histiocytosis (histiocytosis X)-a clonal proliferative disease. N Engl J Med 1994;331:154-60.
3. Yu RC, Chu C, Buluwela L, et al. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet 1994;343:767-8.
4. Willman CL, McClain KL. An update on clonality, cytokines, and viral etiology in Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998;12:407-16.
5. Yousem SA, Colby TV, Chen YY, et al. Pulmonary Langerhans' cell histiocytosis: Molecular analysis of clonality. Am J Surg Pathol 2001;25:630-6.
6. Arico M, Nichols K, Whitlock JA, et al. Familial clustering of Langerhans cell histiocytosis. Br J Haematol 1999;107:883-8.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
8. Weintraub M, Bhatia KG, Chandra RS, et al. p53 expression in Langerhans cell histiocytosis. J Pediatr Hematol Oncol 1998;20:12-7.
9. Savell VH, Sherman T, Scheuermann RH, et al. Bcl-2 expression in Langerhans' cell histiocytosis. Pediatr Dev Pathol 1998;1:210-5.
10. Chu T, D'Angio GJ, Favara BE, et al. Histiocytosis syndromes in children. Lancet 1987;2:41-2.
11. Betts D, Leibundgut K, Feldges A, et al. Cytogenetic abnormalities in Langerhans cell histiocytosis. Br J Cancer 1998;77:552-5.
12. Scappaticci S, Danesino C, Rossi E, et al. Cytogenetic abnormalities in PHA-stimulated lymphocytes from patients with Langerhans cell histocytosis. Br J Haematol 2000;111:258-62.
13. Tazi A, Moreau J, Bergeron A, et al. Evidence that Langerhans cells in adult pulmonary Langerhans cell histiocytosis are mature dendritic cells: Importance of the cytokine microenvironment. J Immunol 1999;163:3511-5.
14. Egeler RM, Favara BE, Laman JD, et al. Abundant expression of CD40 and CD40-ligand (CD154) in paediatric Langerhans cell histiocytosis lesions. Eur J Cancer 2000;36:2105-10.
15. Geissmann F, Lepelletier Y, Fraitag S, et al. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood 2001;97:1241-8.
16. Hage C, Willman CL, Favara BE, et al. Langerhans cell histiocytosis (histiocytosis X): Immunophenotype and growth fraction. Hum Pathol 1993;24:840-5.
17. Markowitz S. TGF-beta receptors and DNA repair genes, coupled targets in a pathway of human colon carcinogenesis. Biochim Biophys Acta 2000:1470:M13-M20.
18. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999;55:96-107.
19. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
20. Basu A, Haldar S. The relationship between Bcl2, Bax and p53: Consequences for cell cycle progression and cell death. Mol Hum Reprod 1998;4:1099-109.
21. El Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
22. El Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated Garrest and apoptosis. Cancer Res 1994;54:1169-74.
23. Bringold F, Serrano M. Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol 2000;35:317-29.
24. Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curt Opin Oncol 1995;7:541-6.
25. Abdelatif OM, Chandler FW, Pantazis CG, et al. Enhanced expression of c-myc and H-ras oncogenes in Letterer-Siwe disease: A sequential study using colorimetric in situ hybridization. Arch Pathol Lab Med 1990;114:1254-60.